$695 | Single User
$1395 | Global License

Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Jun 2015 | 238 | In Stock
Related Topics: AstraZeneca , FDA , Roche

Introduction

Scope


Much of the debate around cancer immunotherapy at the recent ASCO annual meeting focused on the commercial positioning of a new class of product – the PD-1/PD-L1 inhibitors – in second-line, non-small-cell lung cancer (Physician Views Poll Results – Oncologists give thumbs up for Bristol-Myers Squibb's Opdivo despite biomarker jitters and ViewPoints: Biomarker debate diffused by new US treatment guidelines for Opdivo in non-small-cell lung cancer).


Focus is rapidly switching, however, to the opportunity for these products – either as monotherapies or in combinations – in the much larger first-line NSCLC market. This indication could be as much as twice as large as the second-line market, suggests ISI Evercore analyst Mark Schoenebaum, and represents an intriguing showdown given that different drug manufacturers are implementing markedly different development strategies.


Potentially disruptive Phase I/II data in 30 first-line patients were unveiled by Roche at ASCO, demonstrating that the combination of its PD-L1 inhibitor atezolizumab with chemotherapy produced overall response rates above 60 percent. Not only does this data represent a significant benefit over chemotherapy alone (typical response rates of between 20 percent and 30 percent), but the combination demonstrated a similar side-effect profile to that of chemotherapy and exhibited a strong activity irrespective of PD-L1 status.


These data, while needing to be replicated in larger Phase III studies, are significant given that a prominent narrative related to the emergence of immunotherapy has been an assumption that availability of new treatments could remove chemotherapy from the treatment paradigm. Indeed, Bristol-Myers Squibb – which looks poised to lead the market in second-line NSCLC – currently has no registration-supporting studies under way in first-line NSCLC, which combine its PD-1 inhibitor Opdivo with chemotherapy, while Roche is the only company running large-scale Phase III studies.


While Roche's data has gained recognition from analysts and investors since it was published in abstract form ahead of ASCO, this "ground breaking" approach to first-line treatment remains undervalued, argue analysts at Vontobel. The promising data suggest that Roche could assume leadership in the first-line, add analysts, where use of the combination could erode the second-line opportunity as patients become irresponsive after failure in the first-line setting.


With early-stage data indicating that first-line monotherapy use does not confer significant advantages over chemotherapy, but does provide a benefit in terms of tolerability, there could be an opportunity for monotherapy treatment in PD-L1 positive patients (where efficacy is higher) and those patients (approximately 30 percent) intolerant to chemotherapy.


However, if Roche's atezolizumab plus chemotherapy data can be replicated in Phase III studies, this combination could assume significant usage, particularly given the unprecedented uncoupling from a patient's PD-L1 status at baseline, which could support a very broad label, argue analysts.


With PD-1/PD-L1 monotherapy studies in first-line NSCLC targeting PD-L1-positive patients, checkpoint inhibitor combinations (Bristol-Myers Squibb and AstraZeneca are both extensively studying PD-1/PD-L1 inhibitors with a CTLA-4 inhibitor) are aimed largely at PD-L1-negative patients, but are associated with high toxicity (. In a post-ASCO note to investors, analysts at Credit Suisse were left to question whether Roche's atezolizumab plus chemotherapy data has not only significantly raised the efficacy bar, but will prove less costly than a combination of two immunotherapies.


Puchase Reasons


To better ascertain the potential impact of Roche's data in particular, we are asking US and EU5-based oncologists the following questions…


  • Based on Phase I/II overall response rate (ORR) data presented at ASCO, how optimistic are you that the combination of atezolizumab plus chemotherapy will improve the survival of first-line NSCLC patients in a meaningful way?

  • In first-line NSCLC, does the atezolizumab plus chemotherapy data raise the bar for PD-1/PD-L1 monotherapy use in PD-L1-positive patients (demonstrated similar efficacy to chemotherapy, but better tolerability)?

  • In first-line NSCLC, does the atezolizumab plus chemotherapy data raise the bar for combination PD-1/PD-L1 plus CTLA-4 inhibitor use?

  • Assuming the Phase I/II data 'translates' in Phase III studies, what level of usage would you expect for the atezolizumab plus chemotherapy combination in first-line NSCLC patients irrespective of PD-L1 status?

  • Approximately what one-year progression-free survival benefit would a PD-1/PD-L1 inhibitor + CTLA-4 inhibitor combination have to demonstrate in first-line NSCLC to drive moderate-to-significant uptake?hen generic versions of ADF opioids become available do you think they should be required by the FDA to demonstrate…
  • Table of Contents
    for Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    238 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...